Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.07.011Source: DataRank Database

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy is a research paper published in Cancer Cell (2023). On theSindex it has a DataRank of 0. It has been cited 288 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access288 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 34.06)OA: greenTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Patrick M. Forde ORCID,Leisha A. Emens ORCID,Mark Yarchoan ORCID,Kellie N. Smith ORCID,Drew M. Pardoll ORCID

Live enrichment

PubMed:37595586 PMC:PMC10548441 OpenAlex:https://openalex.org/W4385956055

National Institutes of Health

Grant: R37CA251447

National Cancer Institute

Grant: R01 CA142779

Laverna Hahn Charitable Trust

Grant: P50 CA062924

NCI NIH HHS

Grant: P30 CA086862

NCI NIH HHS

Grant: P30 CA006973

NCI NIH HHS

Grant: P30 CA008748

American Lung Association

Barney Family Foundation

Bristol-Myers Squibb

Swim Across America

Mark Foundation For Cancer Research

Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

FWCI

34.06

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10548441/pdf/nihms-1931431.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1535610823002519?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1535610823002519?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10548441

Fields of Study

Cancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasColorectal Cancer Treatments and StudiesHumansNeoadjuvant TherapyImmune Checkpoint InhibitorsImmunotherapyClone CellsNeoplasms

MeSH Terms

Immune Checkpoint InhibitorsClone CellsHumansImmunotherapyNeoplasmsNeoadjuvant Therapy

Keywords

BlockadeImmune checkpointWindow of opportunityImmunotherapyCancer immunotherapyCancerMedicineTherapeutic windowCancer researchImmune systemImmunologyComputer scienceInternal medicineReceptorPharmacologyBiomarkerClinical TrialNeoadjuvantImmune Checkpoint BlockadeAnti-pd-1Multi-omicsAnti-pd-l1

Sustainable Development Goals

SDG 0: Good health and well-being

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

FAIR Checklist

Authors (6)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)